"Discontinuation of Popular Asthma Inhaler in January Raises Concerns Among Experts"
Flovent, a popular asthma inhaler by GSK, will be replaced by an authorized generic version in U.S. pharmacies starting January 1. This change is causing concern among the medical community regarding insurance coverage and potential disruptions during the cold and flu season. GSK assures minimal disruption and potential cost savings, but doctors worry about increased co-pays and access delays, especially for children. The discontinuation is due to Medicaid rebate changes penalizing price increases, with Flovent's price having risen by 47% since 2014. Alternative medications have been suggested in case the generic is not covered by insurers.